Glygen Corp. Launches Patented Micro-Sample Preparation Tools to Interrogate High-Value, Low-Volume Phase II/III Clinical Trial Patient Samples

Glygen Corp. announced today the launch of its patented line of products designed prepare micro-volume Phase II/III clinical trial patient samples for analysis, reducing sample waste and dramatically improving cost-effectiveness of trials.

Glygen's inventions allow scientists to interrogate aliquots less than a microliter in volume of stored clinical trial patient samples. "Glygen aims to help scientists to perform more analyses on smaller volumes of samples with unprecedented sensitivity, specificity, and reproducibility," stated company researchers. "With soaring average per-patient sample costs topping $26,000 for Phase III clinical trials, every microliter counts."

Glygen's patented clinical trial patient sample preparation tools utilize solid-phase extraction (SPE) technology delivered via miniaturized tooling to isolate, purify, and enrich molecules from micro-sample volumes. Glygen's product line includes NuTip, a cartridge embedded with chromatographic media for pipettes and/or liquid handling systems, TopTip, a filterless micro-spin column with packed media, and Lab-in-a-Plate, a media-coated or flow-through plate for multiplexed and automated sample analysis.

In addition to reducing sample waste and improving efficiency, Glygen's tools aim to broaden scientists’ ability to perform complex analyses on patient samples. Typically, the number and type of analyses planned at the outset of a clinical trial are limited by the amount of sample to be collected from patients, with minimizing trial cost and patient imposition of primary concern. Glygen tools enable scientists to plan more complex analyses for clinical trials, which have the potential to yield more comprehensive and/or insightful results.